Get Your Personalized Supplement StackSupplement Stack Quiz

Ivermectin

Q: Is ivermectin effective for COVID-19?

Current high-quality evidence does not support ivermectin reducing mortality or severe outcomes in COVID-19. Systematic reviews and meta-analyses have found no significant benefit.

Q: Is ivermectin safe?

Ivermectin is safe at approved doses for parasitic infections. Off-label use at higher doses should be approached with caution due to potential side effects.

Q: When should ivermectin be taken?

Ivermectin should be taken according to the prescribed indication. For parasitic infections, follow the prescribed dosage. There is no established timing or dosage for COVID-19 treatment.

Q: Are there misconceptions about ivermectin?

Yes, a common misconception is that ivermectin is a proven antiviral for COVID-19. Despite early in vitro studies and anecdotal reports, clinical evidence does not support this.

Also known as: Ivermectin, 22,23-dihydroavermectin B1

Overview

Ivermectin is a semisynthetic derivative of avermectins, compounds originally isolated from the bacterium *Streptomyces avermitilis*. Primarily used as an antiparasitic drug, it is approved for treating infections like onchocerciasis, strongyloidiasis, and scabies. Ivermectin exhibits broad-spectrum antiparasitic activity and has been investigated for potential antiviral and immunomodulatory effects. While well-established for antiparasitic use, its use as a treatment for COVID-19 is investigational and controversial. High-quality evidence supports its antiparasitic applications, but evidence for COVID-19 treatment is mixed, with systematic reviews and meta-analyses indicating limited or no significant benefit. It is available in oral tablet form.

Benefits

Ivermectin is an effective antiparasitic agent with proven efficacy in treating various parasitic infections. However, systematic reviews and meta-analyses have shown no significant reduction in mortality or the need for mechanical ventilation in COVID-19 patients compared to placebo or standard of care. Some studies suggest a possible reduction in mortality in COVID-19 patients in regions with a high prevalence of strongyloidiasis, potentially due to treating co-infections rather than a direct antiviral effect. Meta-analysis indicates no statistically significant mortality benefit in COVID-19, except potentially in areas with high strongyloidiasis prevalence where a mortality risk ratio reduction has been observed.

How it works

Ivermectin binds selectively and with high affinity to glutamate-gated chloride channels in invertebrate nerve and muscle cells, leading to paralysis and death of parasites. In humans, it has limited penetration of the blood-brain barrier, contributing to its safety profile. Proposed antiviral mechanisms include the inhibition of importin α/β-mediated nuclear transport, although the clinical relevance of this mechanism remains unproven. Oral bioavailability is approximately 60-80%, with peak plasma concentrations achieved within 4 hours post-dose.

Side effects

Ivermectin is generally well-tolerated at approved doses for parasitic infections. Common side effects include mild gastrointestinal symptoms such as nausea and diarrhea, as well as dizziness and fatigue. Uncommon side effects (1-5%) may include skin rash and pruritus. Rare side effects (<1%) involve neurological effects, including rare neurotoxicity. Potential drug interactions exist with CYP3A4 inhibitors or inducers. It is contraindicated in individuals with hypersensitivity to ivermectin or its excipients. Caution is advised in pregnant women and children under 15 kg body weight.

Dosage

For parasitic infections, the typical effective dose of ivermectin is 150-200 µg/kg as a single dose. COVID-19 trials have explored dosages of 200-400 µg/kg daily for 1-5 days, but no established effective dose exists for this purpose. Up to 400 µg/kg daily for 5 days has been used in trials without major safety concerns. For parasitic infections, a single or few doses are typically sufficient. Absorption is enhanced when taken with fatty meals. Oral tablets are the standard form of administration.

FAQs

Is ivermectin effective for COVID-19?

Current high-quality evidence does not support ivermectin reducing mortality or severe outcomes in COVID-19. Systematic reviews and meta-analyses have found no significant benefit.

Is ivermectin safe?

Ivermectin is safe at approved doses for parasitic infections. Off-label use at higher doses should be approached with caution due to potential side effects.

When should ivermectin be taken?

Ivermectin should be taken according to the prescribed indication. For parasitic infections, follow the prescribed dosage. There is no established timing or dosage for COVID-19 treatment.

Are there misconceptions about ivermectin?

Yes, a common misconception is that ivermectin is a proven antiviral for COVID-19. Despite early in vitro studies and anecdotal reports, clinical evidence does not support this.

Research Sources

https://pmc.ncbi.nlm.nih.gov/articles/PMC9308124/ – This systematic review and meta-analysis of RCTs (n>3000 patients) found no significant reduction in mortality or mechanical ventilation requirement with ivermectin for COVID-19. The evidence was rated as moderate to low quality with some risk of bias. The review also found no increase in adverse events associated with ivermectin use.
https://academic.oup.com/ofid/article/8/11/ofab358/6316214 – This systematic review, including studies of ivermectin alone or combined with other treatments, showed no mortality benefit in COVID-19 patients. Subgroup analyses based on dose and regimen also failed to demonstrate any significant effect. The quality of evidence was rated as low to moderate due to risk of bias and imprecision.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8470309/ – This meta-analysis stratified results by regional strongyloidiasis prevalence and found a significant mortality reduction only in high-prevalence areas (RR 0.25, p=0.008). This suggests that any observed benefit may be due to the treatment of co-infections rather than a direct antiviral effect of ivermectin. No benefit was observed in low-prevalence areas.
https://journals.lww.com/annals-of-medicine-and-surgery/fulltext/2025/02000/the_impact_of_ivermectin_on_covid_19_outcomes__a.43.aspx – This study investigated the impact of ivermectin on COVID-19 outcomes. The results indicated that ivermectin did not significantly improve outcomes for patients with COVID-19, reinforcing the findings of other meta-analyses and systematic reviews.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790173 – This randomized clinical trial evaluated the efficacy of ivermectin for the treatment of mild to moderate COVID-19. The study found that ivermectin did not significantly reduce the risk of hospitalization or death compared to placebo, further contributing to the evidence against its use as a COVID-19 treatment.